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A B S T R A C T
Antimicrobial peptides (AMPs) are an ancient group of defense molecules distributed in nature being found in
mammals, birds, amphibians, insects, plants, and microorganisms. They display antimicrobial as well as im-
munomodulatory properties. The aim of this study was to investigate, for the first time, the anti-inflammatory
activities of two synthetic temporin-L analogues (here named peptide 1 and 2) by an in vivo model of in-
flammation caused by intraperitoneal sub-lethal dose of zymosan. Our results show that peptide 1 and 2 exert
anti-inflammatory activity in vivo in response to zymosan-induce peritonitis. Simultaneous administration of
10mg/kg of both temporins, with a sub-lethal dose of zymosan (500mg/kg), significantly rescued mice from the
classical hallmarks of inflammation, including leukocyte infiltration and synthesis of inflammatory mediators
including IL-6, TNF-α and MCP-1. More importantly, flow cytometry analysis highlighted a selective modulation
of infiltrating inflammatory monocytes (defined as B220−/GR1hi-F480hi/CD115+) after peptide 2 treatment.
Our results and presented models offer the possibility to test, in a preclinical setting, the potential of temporin
analogues as anti-inflammatory agents.
1. Introduction
The high interest in antimicrobial peptides (AMPs), as new ther-
apeutic agents, is stimulated by their possible use for the treatment of
several infectious diseases, due not only to their antimicrobial activity
but also to their immunomodulatory properties [1].
AMPs represent an abundant group of molecules that are an in-
trinsic component of innate immunity in multicellular organisms and
they show a potent activity against Gram-positive and -negative bac-
teria, fungi and viruses [2]. According to their mode of action, AMPs
can be divided in two main categories, that are membrane disruptive
and no-membrane disruptive AMPs [3]. Membrane disruptive AMPs
present a net positive charge, ranging from +2 to +9, crucial to create
electrostatic interactions with negatively charged cellular membrane of
bacteria, hence disturbing the membrane permeability and causing a
rapid cell death. In this scenario, temporins, first isolated from the skin
secretions of the red frog Rana temporaria, are the largest family of
membrane disruptive AMPs [4]. Structurally, they are among the
smallest sized peptides (10–14 residues) endowed with antimicrobial
activity found in nature to date. The amphibian peptide temporins have
generally, an amidated C-terminus, a low positive charge due to the
presence of 2 or more basic residues in their whole sequence and adopt
an amphipathic α-helical-like preferential conformation in a hydro-
phobic environment [5].
In previous work, we reported a novel library of antimicrobial
peptides correlated to [Pro3, DLeu9]TL (temporin-L derivate), herein
named peptide 1 (Fig. 1), with improved antimicrobial activity [6,7]. In
this context, we uncovered an interesting analogue, herein referred to
as peptide 2 (Fig. 1), which showed a slight increase in activity against
Gram-positive (B. megaterium Bm 11, S. aureus Cowan I, S. epidermidis
ATCC12228), and Gram-negative bacteria (A. baumannii ATCC 19606
and P. aeruginosa ATCC 2785), compared to the reference peptide 1.
Furthermore, peptide 2 was devoid of hemolytic activity and showed a
weak toxicity against human keratinocytes at its antimicrobial con-
centration (12.5 μM) in comparison to 1.
In addition to their antimicrobial activity, the potential therapeutic
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application of AMPs includes an anti-inflammatory and anti-pro-
liferative activity [8–10]. Inflammation is an essential component of the
immune system and represents a defense mechanism against endo- and
exogenous- stimuli, such as pathogens, toxic agents and damaged cells
[11,12]. More recently, different studies have reported that AMPs have
several functions in inflammatory diseases [13] related to their ability
to reduce the levels of proinflammatory cytokines such as tumor ne-
crosis factor-α (TNF-α) and interleukin-6 (IL-6) in lipopolysaccharide
(LPS)-activated macrophages [14].
With this in mind, the aim of our current study was to extend, by
means of both in vitro and in vivo assays, the evaluation of the potential
anti-inflammatory activity of these temporin-L derived peptides in
order to shed some light on the cellular and molecular profiles re-
sponsible for their mode of action.
2. Materials and methods
2.1. Materials
Nα-Fmoc-protected amino acids, Fmoc-Phe, Fmoc-Val, Fmoc-Pro,
Fmoc-Trp(Boc), Fmoc-Ser(tBu), Fmoc-Lys(Boc) and Fmoc-DLys(Boc),
Fmoc-Leu and Fmoc-DLeu, Fmoc-Gly, Fmoc-Ile, Fmoc-Arg(Pbf) were
purchased from GL Biochem Ltd (Shanghai, China). Coupling reagents
such as N,N,N’,N’-tetramethyl-O-(1H-benzotriazol-1-yl) uranium hexa-
fluorophosphate (HBTU) and 1-hydroxybenzotriazole (HOBt), as well
as the Rink amide resin used were commercially obtained by GL
Biochem Ltd (Shanghai, China). N,N-diisopropylethylamine (DIEA),
piperidine, and trifluoroacetic acid (TFA) were purchased from Iris-
Biotech GMBH. Moreover, peptide synthesis solvents and reagents, such
as N,N-dimethylformamide (DMF), dichloromethane (DCM), diethyl
ether (Et2O), water and acetonitrile (MeCN) for HPLC, were reagent
grade acquired from commercial sources (Sigma-Aldrich and VWR) and
used without further purification. Unless otherwise stated, all the other
reagents were from BioCell (Milan, Italy).
2.2. Peptide synthesis
The syntheses of peptides (peptide 1: Phe-Val-Pro-Trp-Phe-Ser-Lys-
Phe-DLeu-Gly-Arg-Ile-Leu NH2, peptide 2: Phe-Val-Pro-Trp- Phe-Ser-
Lys-Phe-DLeu-DLys-Arg-Ile-Leu-NH2, peptide 3: Gly-Phe-Lys-Ser-DLeu-
Trp-Pro-Arg-Phe-Val-Phe-Leu-Ile-NH2, peptide 4: DLys-Phe-Lys-Ser-
DLeu-Trp-Pro-Arg-Phe-Val-Phe-Leu-Ile-NH2) were performed by ap-
plying the innovative ultrasound-assisted solid-phase peptide strategy
(US-SPPS), as elsewhere reported [15]. In brief, each peptide was
constructed on a Rink amide resin (0.1mmol from 0.64mmol/g of
loading substitution) as solid support, using the orthogonal strategy
Fmoc/tBu [Fmoc-deprotections: 20 % Piperidine/DMF, 0.5+ 1min;
couplings: Fmoc-aa (2 equiv), HBTU/HOBt (2 equiv) and DIEA (4
equiv), 5 min]. Finally, peptides were purified and characterized by RP-
HPLC and HReMS spectroscopy, as previously reported [6,15].
2.3. Cell culture
Murine macrophage cell line, J774, was cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10 % fetal bovine serum
(FBS, Cambrex, Verviers, Belgium), L-glutamine (2mM, Sigma, Milan,
Italy), penicillin (100 units/ml, Sigma) and streptomycin (100 μg/ml,
Sigma), and cultured in a humidified 5 % carbon dioxide atmosphere at
37 °C. Cell monolayers were regularly collected by gentle scraping with
a cell scraper, diluted 1:10 in fresh medium and cultured to confluency
at 37 °C. To determine cell responses to peptide 1 and 2, macrophages
were seeded into 96-microwell culture plates at a density of 104 cells/
well and allowed to grow for 24 h. The medium was then replaced with
fresh medium and cells were treated for 4 and 24 h, with a range of
concentrations (1 → 25 μM) of peptide 1 and 2. Positive control in-
cubations were carried out by equivalent concentrations of Diclofenac
and Betamethasone, commonly used preclinically as anti-inflammatory
drugs. In another set of experiments cell were pre-treated with zymosan
(100 ng/ml) followed by peptide 1 and 2 for 4 and 24 h, with the same
range of concentrations. Biological activity of peptides was investigated
by the estimation of a “cell survival index”, arising from the combina-
tion of cell viability evaluation with cell counting. Cell viability was
evaluated using MTT assay, which measures the level of mitochondrial
dehydrogenase activity using the yellow 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT, Sigma) as substrate.
Briefly, after treatments, medium was removed, and cells were in-
cubated with 20 μl/well of MTT solution (5mg/mL) for 1 h in a hu-
midified 5 % CO2 incubator at 37 °C. The incubation was stopped by
removing the MTT solution and by adding 100 μl/well of dimethyl
sulfoxide (DMSO) to solubilize the obtained formazan. Finally, the
absorbance was monitored at 550 nm using a microplate reader (iMark
microplate reader, Bio-Rad, Milan, Italy). Cell number was determined
by TC20 automated cell counter (Bio-Rad, Milan, Italy), providing an
accurate and reproducible total count of cells and a live/dead ratio in
one step by a specific dye (trypan blue) exclusion assay. Bio-Rad’s TC20
automated cell counter uses disposable slides, TC20 trypan blue dye
(0.4 % trypan blue dye w/v in 0.81 % sodium chloride and 0.06 %
potassium phosphate dibasic solution) and a CCD camera to count cells
based on the analyses of captured images. [16].
2.4. Animals
CD-1 male mice (10–14 weeks of age, 25–30 g of weight) were ob-
tained from Charles River (Margate, UK) and kept in an animal care
Fig. 1. Representation of peptide 1 and peptide 2 obtained through a structure-activity relationship (SAR) study of temporin-L. Peptide 3 and 4 represent the
scrambled sequence of peptide 1 and 2, respectively.
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facility under controlled temperature, humidity and on a 12 h:12 h
light:dark cycle, with ad libitum access to water and standard laboratory
chow diet. All experimental procedures were carried out in compliance
with the international and national law and policies (EU Directive
2010/63/EU for animal experiments, ARRIVE guidelines and the Basel
declaration including the 3R concept) [17,18] and approved by Bio-
medical Services Unit at the University of Birmingham (UK). All pro-
cedures were carried out to minimize the number of animals (n= 7 per
group) and their suffering.
2.5. Induction of peritonitis in mice
To examine the anti-inflammatory action of peptide 1 and 2, mice
were randomly divided into different groups: control group (Ctrl),
model group (Zymosan), zymosan+peptides (1, 3 and 10mg/kg)
groups (peptide 1 and 2), and zymosan+dexamethasone (3mg/kg)
group (Dex). Animals received the peptides or Dex intraperitoneally
(i.p.) 30min after i.p. injection of zymosan (500mg/kg) [19]. Ctrl and
model group received an equal volume of vehicle (PBS) according to the
same schedule. Peritonitis was induced in mice as previously described
[20]. In brief, 500mg/kg of zymosan were dissolved in PBS and then
boiled before the i.p. injection (0.5mL) at selected time points (4 and
24 h). Peritoneal exudates were collected by washing the cavity with
2mL of PBS. Then cell number of lavage fluids was determined by TC10
automated cell counter (Bio-Rad, Milan, Italy) using disposable slides,
TC10 trypan blue dye (0.4 % trypan blue dye w/v in 0.81 % sodium
chloride and 0.06 % potassium phosphate dibasic solution) and a CCD
camera to count cells based on the analyses of captured images. The
remaining lavage fluids were centrifuged at 3000 rpm for 20min at 4 °C
and supernatants frozen at −80 °C for further ELISA analysis [21].
2.6. Flow cytometry
Cells collected from the peritoneal cavities were first washed with
PBS and then re-suspended in FACS buffer (PBS containing 1 % FCS and
0.02 % NaN2) containing CD16/CD32 FcγIIR blocking antibody (clone
93; eBioscience, Wembley, UK) for 30min at 4 °C. Thereafter, cells were
labelled for 60min at 4 °C with the following conjugated antibodies (all
from BioLegend, London, UK): GR1 (1:300; clone RB6-8C5), F480
(1:300; clone BM8), B220 (1:200; clone RA3-6B2), CD115 (1:200; clone
AFS98). Neutrophils, macrophages and resident/inflammatory mono-
cytes were defined according to the flow cytometry procedure pre-
viously described [22]. At least 1×104 cells were analysed per sample,
and determination of positive and negative populations was performed
based on the staining obtained with related IgG isotypes. Flow cyto-
metry was performed on BriCyte E6 flow cytometer (Mindray Bio-
Medical Electronics, Nanshan, China) using MRFlow and FlowJo soft-
ware operation.
2.7. Enzyme-linked immunosorbent assay (ELISA)
The levels of TNF-α, IL-6, IL-10 and MCP-1 in the peritoneal exu-
dates at 24 h were measured using commercially available enzyme-
linked immunosorbent assay kit (ELISA kits, eBioscience Co., San
Diego, CA, USA) according to the manufacturer instructions. Briefly,
100 μl of peritoneal exudates, diluted standards, quality controls, and
dilution buffer (blank) were applied on a pre-coated plate with the
monoclonal antibody for 2 h. After washing, 100 μl of biotin-labeled
antibody was added and incubation continued for 1 h. The plate was
washed and 100 μl of the streptavidin–HRP conjugate was added and
the plate was incubated for a further 30min period in the dark. The
addition of 100 μl of the substrate and stop solution represented the last
steps before the reading of absorbance (measured at 450 nm) on a
microplate reader [23,24].
2.8. Statistical analysis
The results obtained were expressed as the mean ± SEM. Statistical
analysis was performed by two-way ANOVA followed by Dunnett's post-
test when comparing more than two groups. In some cases, one sample
Fig. 2. Bioactivity profile of peptides in J774 macrophages. Cell survival index, evaluated by MTT assay, on murine macrophage cell line, following 4 (A) and 24 h
(B) of treatment with selected concentrations (1→25 μM) of peptide 1 and 2. In another set of experiments cells were pre-treate with zymosan (100 ng/ml) followed
by peptide 1 and 2 for 4 (Fig. 2C) and 24 h (Fig. 2D), with the same range of concentrations. Anti-inflammatory positive control incubations were carried out by
equivalent concentrations of Diclofenac and Betamethasone. Data are expressed as percentage of untreated control cells and are reported as mean of five independent
experiments ± S.E.M. *P≤ 0.05, **P≤ 0.01, vs. control cells.
R. Bellavita, et al. Biomedicine & Pharmacotherapy 123 (2020) 109788
3
t-test was used to evaluate significance against the hypothetical zero
value. Statistical analysis was performed by using GraphPad Prism 7.0
software (San Diego, CA, USA). Data were considered statistically sig-
nificant when a value of P≤0.05 was achieved. The data and statistical
analysis comply with the recommendations on experimental design and
analysis [25].
3. Results
3.1. Macrophages biological response to treatments in vitro
The biological activity of peptide 1 and 2 was tested with murine
macrophages J774 cell line. As reported in Fig. 2, the concentration-
effect curves show no interference with cell growth and proliferation up
to the concentration of 20 μM after 4 (A) and 24 h (B) of treatment with
both peptides and anti-inflammatory reference drugs, i.e. Diclofenac
and Betamethasone. However, at 25 μM a slight interference with cell
viability was found for peptide 1 and peptide 2. Indeed, the calculated
IC50 values of both peptides were higher than 80 μM after 4 h and 24 h
of treatment. These values were similar to those measured for beta-
methasone and diclofenac (∼85 and ∼200 μM respectively), herein
used as reference drugs. In another set of experiments cells were pre-
treate with zymosan (100 ng/ml) followed by peptide 1 and 2 for 4
(Fig. 2C) and 24 h (Fig. 2D), with the same range of concentrations.
Although we observed a small reduction in cell vitality after zymosan
treatment, the effect of both peptides was similar to that observed in
“non-stimulated” conditions.
3.2. Anti-inflammatory effect of peptides 1 and 2 in zymosan-induced
peritonitis in mice
In light of the safety of peptide 1 and 2 evidenced through in vitro
evaluations on J774 macrophages, we investigated the role of both
peptides in an in vivo model of inflammation that allowed for the
characterization of leukocyte recruitment and local inflammatory
mediator production. Mice were subjected to i.p. injection of 500mg/
kg zymosan, in the presence or absence of peptide 1 and 2 (1−10mg/
kg dissolved in PBS). As internal control, i.p injection of PBS alone
without zymosan and i.p. injection of Dex (3mg/kg) post zymosan
administration were also assessed. As shown in Fig. 3A, zymosan in-
jection elicited a strong leucocyte recruitment at 4 h (∼ 4.5×106)
which was significantly reduced after peptide 2 administration at a dose
of 10mg/kg (P≤ 0.05). At this time-point the effect of peptide 1
(1−10mg/kg) was not significant compared to mice injected with
peptide 2 and Dex (P≤ 0.005). Conversely, after 24 h both peptides at
10mg/kg significantly reduced (P≤0.05 and P≤0.01 respectively for
peptide 1 and 2) leukocyte infiltration (∼11×106 after zymosan
injection) with a profile, for peptide 2, comparable to Dex (P≤0.01).
Interestingly, peptide 2 also displayed significant effects at a lower dose
of 3mg/kg (P≤ 0.05) (Fig. 3B). Other experimental groups also in-
cluded mice that received zymosan with peptide 1 and 2 at the highest
dose (10mg/kg) inactivated by denaturation or peptides with scram-
bled aminoacidic assembly. As shown in Fig. 4, both peptides at 24 h
did not display any significant inhibitory effects on leukocyte recruit-
ment.
3.3. Modulation of cellular inflammatory infiltrates by peptides 1 and 2
Previous studies have shown that a single administration of zy-
mosan into the peritoneal cavity causes a transient infiltration of leu-
kocytes that becomes evident between 4–24 h, which declines by 48 h.
To test the effects of an acute systemic administration of peptide 1 and
2, we administered these peptides with the same dose (10mg/kg) that
evoked the optimal inhibition of leukocyte recruitment to the perito-
neum. All mice were sacrificed 24 h after zymosan administration.
Consistent with our previous findings, 24 h after a single injection of
zymosan (500mg/kg) i.p there was a significant increase in the levels of
TNF-α, IL-6, IL-10 and MCP-1 compared to the control group (Fig. 5A,
Fig. 3. Anti-inflammatory effect of tem-
porin-derived peptides in zymosan-in-
duced peritonitis in mice. Mice (n=7)
were injected intraperitoneally with
500mg/kg zymosan, with 500mg/kg
zymosan and 1−10mg/kg of peptides 1
and 2 or 500mg/kg zymosan and 3mg/
kg of dexamethasone (Dex). At 4 (A) and
24 h (B) after zymosan injection, perito-
neal essudate from each mouse was re-
covered and total cell number (expressed
as 1×106 and normalized to exudate
levels) was evaluated. Results are ex-
pressed as mean ± S.E.M. ++P≤0.01,
+++P≤0.005 vs. ctrl group, *P≤0.05,
**P≤0.01 and ***P≤0.005 compared
to zymosan-treated mice.
Fig. 4. Effect of denatured and scrambled temporin-derived peptides in zy-
mosan-induced peritonitis in mice. Mice (n= 7) were injected intraperitoneally
with 500mg/kg zymosan, with 500mg/kg zymosan and 10mg/kg of peptides
1 and 2 or 500mg/kg zymosan and peptides (1 and 2) denatured and scram-
bled (10mg/kg). At 24 h post injection, peritoneal essudate from each mouse
was recovered and total cell number (expressed as 1× 106 and normalized to
exudate levels) was evaluated. Results are expressed as mean ± S.E.M.
++P≤0.01 compared vs. ctrl group, *P≤0.05 and **P≤ 0.01 vs. zymosan-
treated mice.
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B, C and D respectively). Interestingly, peptide 1 at 10mg/kg sig-
nificantly (p≤0.05) reduced the levels of TNF-α (Fig. 5A) and IL-6
(Fig. 5B). The levels of IL-10 (Fig. 5C) and MCP-1 (Fig. 5D) remained
unaffected. Similarly, peptide 2, at the same dose, also reduced
(p≤0.01) the levels of TNF-α (Fig. 5A) and IL-6 (Fig. 5B), but a re-
duction was also observed in (p≤0.05) MCP-1 (Fig. 5D). Injection of
the positice control Dex (3mg/kg) decreased the values of mentioned
cyto-chemokines (Fig. 5A, B, C and D) with a profile comparable to
peptide 2.
Based on these results, we selected the most active temporin L-de-
rived peptide (peptide 2) to investigate the phenotype of inflammatory
leukocytes recruited to the peritoneal cavity. Leucocytes collected at
24 h time-point post zymosan injection were stained with an anti-B220,
anti-F480, anti-GR1, anti-CD115 antibodies and then analyzed by flow
cytometry. We did not observe any significant difference in terms of
neutrophils (GR1+ cells) and macrophages (F4/80+ cells) reduction
after peptide 2 treatment (data not shown). However, to identify po-
tential differences in monocyte subpopulations, total cells were gated
on their totality (Fig. 6A, gate R1) and singlet (Fig. 6B, gate R2) for the
identification of B220− population (Fig. 6C, gate R3) followed by GR1
and F480 expression (Fig. 6D–F). Double high positive population for
these markers (Gate R4, 9.05 ± 0.32, 41.20 ± 2.78 and
31.70 ± 2.55 of double high positive population respectively for Ctrl,
zymosan and zymosan+ peptide 2; Fig. 6J) were then further inter-
rogated for CD115 (Fig. 6G–I) as its expression level is commonly
correlated with the degree of maturation of inflammatory monocytes.
Our results show that in zymosan-injected mice, most cells recovered
were B220−/GR1hi-F480hi/CD115+ (10.70 ± 1.14 compared to
2.70 ± 0.24 of Ctrl) with a significant lower expression in peptide 2-
treated group (3.24 ± 1.41) (Fig. 6K). These values were strengthened
by a low percentage of positive cells found in the staining for the iso-
type control antibodies (Supplementary Fig. 1).
4. Discussion
The most important result of this work is that peptide 2, a synthetic
analog of temporin-L, displayed potent anti-inflammatory activity in a
well characterised in vivo model of acute inflammation. This was ex-
emplified by its ability to inhibit the recruitment of inflammatory
monocytes and dampen the production of pro-inflammatory mediators
IL-6, MCP-1 and TNF-α. This activity of peptide 2 was also shown not to
detrimentally impact the ability of macrophages to grow or proliferate
in vitro.
In fact peptide 2 showed a remarkable biocompatibility profile in
our experimental model especially at the lower micromolar range al-
lowing for a safe animal experimentation. The concentration-effect
curves on J774 cell line showed no interference with cell growth and
proliferation up to the concentration of 20 μM after 4 and 24 h of
treatment with both peptides and anti-inflammatory reference drugs,
i.e. Diclofenac and Betamethasone. Interestingly, this profile was si-
milar to that observed after co-stimulation of murine macrophages with
zymosan and both peptide 1 and 2 [27,28].
Zymosan, a polysaccharide cell wall component derived from
Saccharomyces cerevisiae, has been reported to elicit a multiple organ
failure and a massive recruitment of innate immunity cells in the
peritoneal cavity, mainly characterized by neutrophils and monocytes
[26]. The organ dysfunction in zymosan treated animals may be, in
part, dependent on bacterial translocation [29]. The role of the pro-
duction of pro-inflammatory cytokines, such as IL-1, IL-6, TNF-α
[30,31] and of prostaglandin metabolites [29] with consequent cellular
infiltration and exudate formation is well established in the patho-
physiology of zymosan-induced shock. TNF-α plays a pivotal role
characterized by the release of IL-1 and IL-6 that orchestrate neutrophil,
macrophage, and fibroblast accumulation to the site of inflammation
[32,33]. This scenario is supported by the CC chemokine MCP-1, as one
of the most potent chemotactic factors for monocyte migration to the
site of tissue injury [34]. On the other hand, IL-10 is an anti-in-
flammatory cytokine that mainly suppresses inflammatory response by
Fig. 5. Cyto-chemokines analysis of collected peritoneal exudates. Analysis of collected peritoneal exudates identified heightened levels of the classical pro-in-
flammatory cyto-chemokines TNF-α (A), IL-6 (B), IL-10 (C), and MCP-1 (D) in the peritoneal cavity of mice from zymosan groups (n=7). Significant differences
were found in relative levels after temporin 1 and 2 administration (n=7). Results (normalized to exudate levels) are expressed as mean ± S.E.M. +P≤0.05 and
++P≤0.01 vs. ctrl group, *P≤0.05 and **P≤ 0.01 vs. zymosan-treated mice.
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increasing anti-inflammatory factors and inhibiting the activation and
function of T cells and monocytes [35]. Accordingly, it is well known
that the use of zymosan as experimental model of inflammation results
in a range of benefits. Following the injection with zymosan, it is pos-
sible to collect a reasonable amount of exudate for the analysis of
several inflammatory mediators, furthemore, injection into a serosal
cavity instead of an artificiall formed cavity, such as a sterile air pouch,
means that leukocytes exit from the site of inflammation via their
natural conduits to the draining lymph nodes [36,37].
Our results demonstrate that the zymosan-induced leukocytes re-
cruitment was attenuated by treatment with peptide 2, at the highest
dose examined, starting from 4 h post zymosan administration. A si-
milar trend was observed for peptide 1, however, the degree of at-
tenuation was not similarly significant. Interestingly, at 24 h both
peptides significantly attenuated inflammatory cell migration to the
peritoneal cavity, but even at this time point peptide 2 appeared to be
more potent when compared to littermate compound. Moreover, de-
naturized or scrambled sequence of both peptides administrated at
10mg/kg did not display any biological effects highlighting the hy-
pothesis that only “selected peptides sequence” elicited observed anti-
inflammatory effects. Lending support to these findings, a screening of
the main pro-inflammatory cytokines showed a significant reduction in
the levels of IL-6, MCP-1 and TNF-α after peptide 2, and to a lesser
extent with peptide 1. However, we did not reveal any modulation of
IL-10 after both peptides administration. This difference in leukocytes
accumulation and cytokines level may be due to the difference in po-
tency of these two analogues and to assess this possibility, further an-
imal studies will be carried out using other in vivo models as well other
structural analogues.
To investigate and compare the phenotype of the inflammatory
leukocytes recruited by zymosan injection into peritoneal cavity, we
first gated on cells isolated from peritoneal exudates for B220− popu-
lation, followed by GR1hi/F480hi expression to finally identify the level
of CD115+, commonly correlated with the degree of maturation of
inflammatory monocytes [22,23]. We did not observe any significant
difference in terms of neutrophil and macrophage levels after peptide 2
treatment. However, our FACS analysis showed that in zymosan-in-
jected mice, most cells recovered were inflammatory monocytes with a
significant lower expression observed in peptide 2-treated mice.
5. Conclusion
In conclusion, we have demonstrated, for the first time, the anti-
inflammatory activity of peptide 2 reinforcing the idea that selected
AMP could be effectively used as antisepsis agents in vivo due to its
ability to modulate the recruitment of inflammatory monocytes. In fu-
ture studies, it would be interesting to explore the antiendotoxin
properties of other temporins-derivatives and synthetic analogues even
in combination with conventional antibiotics, in way to acquire key
information needed to assist the design of improved endotoxin-neu-
tralizing temporin-based peptides for therapeutic applications.
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Fig. 6. Flow cytometry strategy applied to identify the modulation of inflammatory monocytes in zymosan and zymosan+ peptide 2-treated group. Cells obtained at
24 h time-point post zymosan injection in all experimental conditions were washed and stained with the following panel of antibodies: anti-B220, anti-F480, anti-GR1
and anti-CD115. Specifically, to identify potential differences in monocyte subpopulations, total cells were gated for their totality (A, gate R1) and singlet (B, gate R2)
to identify B220− population (C, gate R3) followed by GR1 and F480 expression (D-F). Double high positive population for these markers (gate R4) was then further
interrogated for CD115 (G-I) The numbers in the dot plots indicated the percentage of positively stained cells after gating strategy. FACS plots are representative of
seven samples with similar results. Results (normalized to exudate levels) are presented as mean ± S.E.M (J and K) of n= 7 mice per group. +++P≤0.001 vs. ctrl
group, *P≤ 0.05 and **P≤ 0.01 vs. zymosan-treated mice.
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Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.biopha.2019.109788.
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